

Colin L Masters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8651950/publications.pdf>

Version: 2024-02-01

521
papers

54,984
citations

1981

104
h-index

1801

217
g-index

567
all docs

567
docs citations

567
times ranked

40922
citing authors

#	ARTICLE	IF	CITATIONS
1	Biomarker clustering in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 274-284.	0.4	2
2	Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney. <i>Alzheimer's and Dementia</i> , 2022, 18, 178-190.	0.4	5
3	Deep Generative Medical Image Harmonization for Improving Cross-Site Generalization in Deep Learning Predictors. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 908-916.	1.9	38
4	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1141-1154.	0.4	89
5	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 1295-1305.	1.3	10
6	No Influence of Age-Related Hearing Loss on Brain Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2022, 85, 359-367.	1.2	6
7	Analysis of plasma proteins using 2D gels and novel fluorescent probes: in search of blood based biomarkers for Alzheimer's disease. <i>Proteome Science</i> , 2022, 20, 2.	0.7	6
8	ϵ -APOE ϵ 2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies. <i>Alzheimer's and Dementia</i> , 2022, 18, 2151-2166.	0.4	16
9	Association of ϵ -BDNF Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 261.	4.5	15
10	Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings. <i>Alzheimer's and Dementia</i> , 2022, 18, 2218-2233.	0.4	24
11	Plasma microRNA vary in association with the progression of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12251.	1.2	11
12	Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12307.	1.2	14
13	Cerebrospinal fluid Alzheimer disease biomarkers for assessing cognitive and neuropsychiatric symptoms: Expanding the "toolkit" in the psychiatrist's diagnostic armamentarium. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 865-866.	1.3	1
14	The Association Between Alzheimer's Disease-Related Markers and Physical Activity in Cognitively Normal Older Adults. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 771214.	1.7	8
15	Mesial temporal tau in amyloid- β -negative cognitively normal older persons. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 51.	3.0	12
16	Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer's disease. <i>Science Advances</i> , 2022, 8, eabm5667.	4.7	6
17	Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF A β 242 moderates the association between insulin resistance and increased CSF tau levels. <i>Neurobiology of Aging</i> , 2022, 114, 38-48.	1.5	5
18	Validation of Plasma Amyloid- β 42/40 for Detecting Alzheimer Disease Amyloid Plaques. <i>Neurology</i> , 2022, 98, .	1.5	89

#	ARTICLE	IF	CITATIONS
19	Enhanced ion mobility resolution of Aβ isomers from human brain using high-resolution demultiplexing software. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 5683-5693.	1.9	8
20	Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume. <i>GeroScience</i> , 2022, 44, 1807-1823.	2.1	19
21	Differential Effects of APOE and Modifiable Risk Factors on Hippocampal Volume Loss and Memory Decline in Aβ ⁻ and Aβ ⁺ Older Adults. <i>Neurology</i> , 2022, 98, e1704-e1715.	1.5	4
22	Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study. <i>Biomedicine</i> , 2022, 10, 1045.	1.4	1
23	Autosomal dominant and sporadic late onset Alzheimer's disease share a common <i>in vivo</i> pathophysiology. <i>Brain</i> , 2022, 145, 3594-3607.	3.7	20
24	Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer's disease. <i>BMC Genomics</i> , 2022, 23, .	1.2	1
25	Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-β. <i>Neurobiology of Disease</i> , 2022, 171, 105783.	2.1	5
26	Amyloid-β (Aβ)-Related Cerebral Amyloid Angiopathy Causing Lobar Hemorrhage Decades After Childhood Neurosurgery. <i>Stroke</i> , 2022, 53, .	1.0	6
27	Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-11.	1.2	7
28	Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7867.	1.8	5
29	Association of β ² -Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. <i>Neurology</i> , 2021, 96, e662-e670.	1.5	34
30	The BDNF Val66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 614-628.	4.1	61
31	Aggregation of Abnormal Memory Scores and Risk of Incident Alzheimer's Disease Dementia: A Measure of Objective Memory Impairment in Amnesic Mild Cognitive Impairment. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 146-157.	1.2	3
32	Polygenic score modifies risk for Alzheimer's disease in APOE ε4 homozygotes at phenotypic extremes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12226.	1.2	7
33	Learning deficit in cognitively normal APOE ε4 carriers with LOW β ² -amyloid. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12136.	1.2	7
34	Presymptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy-Related Blood Metabolite Alterations. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 895-903.	1.2	5
35	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12197.	1.2	4
36	Association of naturally occurring antibodies to β ² -amyloid with cognitive decline and cerebral amyloidosis in Alzheimer's disease. <i>Science Advances</i> , 2021, 7, .	4.7	26

#	ARTICLE	IF	CITATIONS
37	<i>BDNF</i> VAL66MET polymorphism and memory decline across the spectrum of Alzheimer's disease. <i>Genes, Brain and Behavior</i> , 2021, 20, e12724.	1.1	14
38	Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies. <i>NeuroImage</i> , 2021, 226, 117593.	2.1	15
39	Visual Memory Deficits in Middle-Aged APOE ϵ 4 Homozygotes Detected Using Unsupervised Cognitive Assessments. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1563-1573.	1.2	4
40	SPON1 Is Associated with Amyloid- β 2 and APOE ϵ 4-Related Cognitive Decline in Cognitively Normal Adults. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 111-120.	1.2	5
41	Deficits in Monocyte Function in Age Related Macular Degeneration: A Novel Systemic Change Associated With the Disease. <i>Frontiers in Medicine</i> , 2021, 8, 634177.	1.2	10
42	Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2931.	1.8	10
43	Genetic testing in dementia—a medical genetics perspective. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1158-1170.	1.3	9
44	Quantification of N-terminal amyloid- β 2 isoforms reveals isomers are the most abundant form of the amyloid- β 2 peptide in sporadic Alzheimer's disease. <i>Brain Communications</i> , 2021, 3, fcab028.	1.5	25
45	Relevance of a Truncated PRESENILIN 2 Transcript to Alzheimer's Disease and Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1479-1489.	1.2	4
46	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. <i>Brain Connectivity</i> , 2021, 11, 239-249.	0.8	18
47	Core Alzheimer's disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 79.	3.0	0
48	Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults. <i>Psychological Science</i> , 2021, 32, 849-860.	1.8	8
49	Bundle-specific associations between white matter microstructure and β 2 and tau pathology in preclinical Alzheimer's disease. <i>ELife</i> , 2021, 10, .	2.8	26
50	Characterization of brain-derived extracellular vesicle lipids in Alzheimer's disease. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12089.	5.5	64
51	Androgen receptor CAG repeat length as a moderator of the relationship between free testosterone levels and cognition. <i>Hormones and Behavior</i> , 2021, 131, 104966.	1.0	2
52	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 443-468.	1.2	59
53	Longitudinal Trajectories in Cortical Thickness and Volume Atrophy: Superior Cognitive Performance Does Not Protect Against Brain Atrophy in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1039-1052.	1.2	2
54	Deaths with Dementia in Indigenous and Non-Indigenous Australians: A Nationwide Study. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1589-1599.	1.2	2

#	ARTICLE	IF	CITATIONS
55	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	15.2	182
56	Comparing amyloid- β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. <i>Acta Neuropathologica</i> , 2021, 142, 689-706.	3.9	15
57	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. <i>Lancet Neurology</i> , The, 2021, 20, 615-626.	4.9	26
58	The Amyloid- β Pathway in Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2021, 26, 5481-5503.	4.1	478
59	Citrullination of Amyloid- β Peptides in Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2021, 12, 3719-3732.	1.7	10
60	Modeling autosomal dominant Alzheimer's disease with machine learning. <i>Alzheimer's and Dementia</i> , 2021, 17, 1005-1016.	0.4	12
61	Relationship between amyloid and tau levels and its impact on tau spreading. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2225-2232.	3.3	30
62	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1632-e1645.	1.5	16
63	A six-metabolite panel as potential blood-based biomarkers for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 94.	2.5	19
64	Genomics of Alzheimer's disease implicates the innate and adaptive immune systems. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 7397-7426.	2.4	32
65	Effects of a physical activity intervention on brain atrophy in older adults at risk of dementia: a randomized controlled trial. <i>Brain Imaging and Behavior</i> , 2021, 15, 2833-2842.	1.1	1
66	Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD): A Report of an International Research Collaboration Network. <i>Journal of Alzheimer's Disease</i> , 2021, , 1-15.	1.2	1
67	A Paradox in Digital Memory Assessment: Increased Sensitivity With Reduced Difficulty. <i>Frontiers in Digital Health</i> , 2021, 3, 780303.	1.5	2
68	Higher Coffee Consumption Is Associated With Slower Cognitive Decline and Less Cerebral $A\beta$ -Amyloid Accumulation Over 126 Months: Data From the Australian Imaging, Biomarkers, and Lifestyle Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 744872.	1.7	17
69	A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure. <i>Nature Communications</i> , 2021, 12, 7065.	5.8	38
70	Differential associations of modifiable and non-modifiable dementia risk factors with memory decline and hippocampal volume loss in $A\beta$ - and $A\beta$ + cognitively normal older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
71	Lipidomic signatures for APOE genotypes provides new insights about mechanisms of resilience in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
72	Using imputation to provide harmonized longitudinal measures of cognition across AIBL and ADNI. <i>Scientific Reports</i> , 2021, 11, 23788.	1.6	16

#	ARTICLE	IF	CITATIONS
73	Could cerebrospinal fluid neurofilament light chain reduce misdiagnosis in neurodegenerative and neuropsychiatric disorders in a real-world setting? A retrospective clinical and diagnostic utility study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
74	A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A β -C-reactive protein TM for psychiatrists and neurologists?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 57-67.	1.3	40
75	Effect of a 24-month physical activity program on brain changes in older adults at risk of Alzheimer's disease: the AIBL active trial. <i>Neurobiology of Aging</i> , 2020, 89, 132-141.	1.5	28
76	Increased cerebral blood flow with increased amyloid burden in the preclinical phase of alzheimer's disease. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 505-513.	1.9	35
77	Use of an experimental language acquisition paradigm for standardized neuropsychological assessment of learning: A pilot study in young and older adults. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2020, 42, 55-65.	0.8	10
78	Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning. <i>Information Fusion</i> , 2020, 58, 153-167.	11.7	17
79	Cerebrospinal fluid neurofilament light chain is elevated in Niemann-Pick type C compared to psychiatric disorders and healthy controls and may be a marker of treatment response. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 648-649.	1.3	18
80	Harmonization of large MRI datasets for the analysis of brain imaging patterns throughout the lifespan. <i>NeuroImage</i> , 2020, 208, 116450.	2.1	260
81	Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. <i>Alzheimer's and Dementia</i> , 2020, 16, 552-560.	0.4	55
82	Influence of Comorbidity of Cerebrovascular Disease and Amyloid- β^2 on Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 897-907.	1.2	21
83	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. <i>Brain Communications</i> , 2020, 2, fcaa102.	1.5	11
84	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102491.	1.4	17
85	Intra-cerebral haemorrhage but not neurodegenerative disease appears over-represented in deaths of Australian cadaveric pituitary hormone recipients. <i>Journal of Clinical Neuroscience</i> , 2020, 81, 78-82.	0.8	2
86	Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 5698.	5.8	76
87	Evaluation of GammaH2AX in Buccal Cells as a Molecular Biomarker of DNA Damage in Alzheimer's Disease in the AIBL Study of Ageing. <i>Life</i> , 2020, 10, 141.	1.1	2
88	Sequence of Alzheimer disease biomarker changes in cognitively normal adults. <i>Neurology</i> , 2020, 95, e3104-e3116.	1.5	35
89	Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer's Disease Patients and Correlates with Cognitive Performance. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 733-744.	1.2	7
90	Association of deficits in short-term learning and $A\beta^2$ and hippocampal volume in cognitively normal adults. <i>Neurology</i> , 2020, 95, e2577-e2585.	1.5	31

#	ARTICLE	IF	CITATIONS
91	Longitudinal evaluation of the natural history of amyloid- β^2 in plasma and brain. <i>Brain Communications</i> , 2020, 2, fcaa041.	1.5	21
92	Plasma Amyloid- β^2 Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1057-1065.	1.2	27
93	Morphometric Changes to Corneal Dendritic Cells in Individuals With Mild Cognitive Impairment. <i>Frontiers in Neuroscience</i> , 2020, 14, 556137.	1.4	20
94	The anti-amyloid treatment in asymptomatic Alzheimer's disease (A4) study: Report of screening and recruitment characteristics of the Melbourne composite site. <i>Alzheimer's and Dementia</i> , 2020, 16, e042786.	0.4	0
95	Risk factors for falls in preclinical and prodromal Alzheimer's disease and dementia due to Alzheimer's disease: Findings from the Australian Imaging, Biomarker and Lifestyle study of ageing (AIBL). <i>Alzheimer's and Dementia</i> , 2020, 16, e044954.	0.4	0
96	The function and composition of brain tissue derived exosomes in human Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045561.	0.4	0
97	Relationship of Established Cardiovascular Risk Factors and Peripheral Biomarkers on Cognitive Function in Adults at Risk of Cognitive Deterioration. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 163-171.	1.2	13
98	Small RNA fingerprinting of Alzheimer's disease frontal cortex extracellular vesicles and their comparison with peripheral extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1766822.	5.5	59
99	Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 27-31.	1.2	8
100	Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 303-315.	1.2	23
101	Plasma transferrin and hemopexin are associated with altered $A\beta^2$ uptake and cognitive decline in Alzheimer's disease pathology. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 72.	3.0	19
102	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2020, 26, 398-407.	15.2	351
103	Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12005.	1.2	35
104	Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 22.	3.0	74
105	MRI signatures of brain age and disease over the lifespan based on a deep brain network and 14%468 individuals worldwide. <i>Brain</i> , 2020, 143, 2312-2324.	3.7	183
106	Optimizing red blood cell protein extraction for biomarker quantitation with mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2020, 412, 1879-1892.	1.9	9
107	Baseline White Matter Is Associated With Physical Fitness Change in Preclinical Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 115.	1.7	7
108	Total $A\beta^2$ / $A\beta^40$ ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. <i>Neurology</i> , 2020, 94, e1580-e1591.	1.5	102

#	ARTICLE	IF	CITATIONS
109	Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 36.	3.0	39
110	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learning. <i>Alzheimer's and Dementia</i> , 2020, 16, 501-511.	0.4	47
111	Major risk factors for Alzheimer's disease: age and genetics. <i>Lancet Neurology</i> , The, 2020, 19, 475-476.	4.9	12
112	Comorbidity of Cerebrovascular and Alzheimer's Disease in Aging. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 321-334.	1.2	4
113	Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-A β load and cerebrospinal fluid A β in a pilot study of Alzheimer's disease. <i>Neuroscience Letters</i> , 2020, 731, 135078.	1.0	6
114	Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β -Associated Cognitive Decline in Older Adults. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 585-598.	0.3	23
115	Determining clinically meaningful decline in preclinical Alzheimer disease. <i>Neurology</i> , 2019, 93, e322-e333.	1.5	96
116	The dawn of robust individualised risk models for dementia. <i>Lancet Neurology</i> , The, 2019, 18, 985-987.	4.9	6
117	Genetic resilience to Alzheimer's disease in ϵ /4 homozygotes: A systematic review. <i>Alzheimer's and Dementia</i> , 2019, 15, 1612-1623.	0.4	21
118	A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials. <i>Alzheimer's and Dementia</i> , 2019, 15, 1448-1457.	0.4	7
119	Rates of age- and amyloid β -associated cortical atrophy in older adults with superior memory performance. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 566-575.	1.2	21
120	Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease. <i>Nature Communications</i> , 2019, 10, 4227.	5.8	157
121	Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 670-678.	1.2	19
122	Characterization of the metal status of natively purified alpha-synuclein from human blood, brain tissue, or recombinant sources using size exclusion ICP-MS reveals no significant binding of Cu, Fe or Zn. <i>Metallomics</i> , 2019, 11, 128-140.	1.0	13
123	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. <i>Nature Medicine</i> , 2019, 25, 277-283.	15.2	610
124	Klotho allele status is not associated with A β and APOE ϵ 4-related cognitive decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 76, 162-165.	1.5	23
125	Method comparison study of the Elecsys β -Amyloid (1 \times 42) CSF assay versus comparator assays and LC-MS/MS. <i>Clinical Biochemistry</i> , 2019, 72, 7-14.	0.8	30
126	Avoiding methodological bias in studies of amyloid imaging results disclosure. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 52.	3.0	3

#	ARTICLE	IF	CITATIONS
127	Comparison of ¹⁸ F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL approaches: Validation against histopathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 807-816.	0.4	50
128	COMT val158met is not associated with A β -amyloid and APOE ϵ 4 related cognitive decline in cognitively normal older adults. <i>IBRO Reports</i> , 2019, 6, 147-152.	0.3	5
129	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2019, 142, 1429-1440.	3.7	36
130	ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. <i>Neurology</i> , 2019, 92, e1567-e1579.	1.5	73
131	To What Extent Does Age at Death Account for Sex Differences in Rates of Mortality From Alzheimer Disease?. <i>American Journal of Epidemiology</i> , 2019, 188, 1213-1223.	1.6	30
132	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 180-190.	1.2	84
133	Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2019, 41, 591-600.	0.8	18
134	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. <i>Science Advances</i> , 2019, 5, eaau7220.	4.7	59
135	Decrease in p3 β Alc β 237 and p3 β Alc β 240, products of Alc β generated by β secretase cleavages, in aged monkeys and patients with Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 740-750.	1.8	6
136	ICP-167: AUTOMATED REPORTING OF TAU PET QUANTIFICATION ON BRAIN SURFACE. <i>Alzheimer's and Dementia</i> , 2019, 15, P131.	0.4	2
137	ICP-004: CORRECTING FOR PET SCANNER CHANGES IN LONGITUDINAL STUDIES. <i>Alzheimer's and Dementia</i> , 2019, 15, P15.	0.4	0
138	ICP-017: AMYLOID PET IS MORE THAN JUST POSITIVE OR NEGATIVE: AMYLOID LEVEL IMPACTS RISK OF CLINICAL PROGRESSION IN NORMAL INDIVIDUALS. <i>Alzheimer's and Dementia</i> , 2019, 15, P26.	0.4	0
139	Validation of a priori candidate Alzheimer's disease SNPs with brain amyloid-beta deposition. <i>Scientific Reports</i> , 2019, 9, 17069.	1.6	15
140	An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. <i>Nature Neuroscience</i> , 2019, 22, 1903-1912.	7.1	242
141	A Randomized Controlled Trial of Adherence to a 24-Month Home-Based Physical Activity Program and the Health Benefits for Older Adults at Risk of Alzheimer's Disease: The AIBL Active-Study. <i>Journal of Alzheimer's Disease</i> , 2019, 70, S187-S205.	1.2	18
142	Seizures as an early symptom of autosomal dominant Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 76, 18-23.	1.5	27
143	Multisite study of the relationships between <i>antemortem</i> [¹¹ C]PIB-PET Centiloid values and <i>postmortem</i> measures of Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 205-216.	0.4	155
144	Visual paired associate learning deficits associated with elevated beta-amyloid in cognitively normal older adults.. <i>Neuropsychology</i> , 2019, 33, 964-974.	1.0	17

#	ARTICLE	IF	CITATIONS
145	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. <i>Brain</i> , 2018, 141, 1186-1200.	3.7	83
146	Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain A β -amyloid burden. <i>Translational Psychiatry</i> , 2018, 8, 47.	2.4	92
147	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. <i>Brain</i> , 2018, 141, 1486-1500.	3.7	79
148	Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer's disease. <i>Personalized Medicine in Psychiatry</i> , 2018, 7-8, 14-20.	0.1	13
149	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. <i>Lancet Neurology</i> , The, 2018, 17, 241-250.	4.9	383
150	Associations of Dietary Protein and Fiber Intake with Brain and Blood Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1589-1598.	1.2	44
151	Imaging tau and amyloid- β proteinopathies in Alzheimer disease and other conditions. <i>Nature Reviews Neurology</i> , 2018, 14, 225-236.	4.9	321
152	High performance plasma amyloid- β biomarkers for Alzheimer's disease. <i>Nature</i> , 2018, 554, 249-254.	13.7	1,180
153	KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ϵ 4-positive cognitively normal adults with high A β -amyloid burden. <i>Scientific Reports</i> , 2018, 8, 2034.	1.6	31
154	Association of β -Amyloid and Apolipoprotein E ϵ 4 With Memory Decline in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2018, 75, 488.	4.5	70
155	Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease. <i>Journal of Affective Disorders</i> , 2018, 229, 269-274.	2.0	27
156	Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategiesâ€”Gains from AIBL and DIAN Cohort Studies. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 965-992.	1.2	96
157	Baseline Amnesic Severity Predicts Progression From Amnesic Mild Cognitive Impairment to Alzheimer Disease Dementia at 3 Years. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 190-196.	0.6	19
158	CSF Tau supplements 14-3-3 protein detection for sporadic Creutzfeldtâ€”Jakob disease diagnosis while transitioning to next generation diagnostics. <i>Journal of Clinical Neuroscience</i> , 2018, 50, 292-293.	0.8	9
159	Trajectories of depressive and anxiety symptoms in older adults: a 6â€”year prospective cohort study. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 405-413.	1.3	20
160	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study. <i>Alzheimer's and Dementia</i> , 2018, 14, 43-53.	0.4	42
161	P2â€”364: TAU IMAGING IN ALZHEIMER'S DISEASE WITH [Fâ€”18]â€”MK6240, A SECOND GENERATION SELECTIVE TAU TRACER. <i>Alzheimer's and Dementia</i> , 2018, 14, P831.	0.4	0
162	ICâ€”Pâ€”223: TO TAU OR TO MAOâ€”B? MOST OF THE [Fâ€”18]â€”THK5351 SIGNAL IS BLOCKED BY SELEGILINE. <i>Alzheimer's and Dementia</i> , 2018, 14, P181.	0.4	0

#	ARTICLE	IF	CITATIONS
163	P1â€405: VISUAL ASSESSMENT OF Î²â€AMYLOID PET SCAN IS IMPROVED BY CAPAIBL. Alzheimer's and Dementia, 2018, 14, P459.	0.4	0
164	O4â€09â€01: COMPARISON OF THE NATURAL HISTORY OF NEOCORTICAL AÎ²â€AMYLOID, HIPPOCAMPAL VOLUME AND PACC IN SPORADIC AD. Alzheimer's and Dementia, 2018, 14, P1423.	0.4	0
165	P3â€494: EXAMINING THE INFLUENCE OF UNDETECTED ATN NEUROPATHOLOGY ON COGNITIVE AGING TRAJECTORIES. Alzheimer's and Dementia, 2018, 14, P1311.	0.4	0
166	P3â€620: INCREASED PROTEIN AND FIBRE INTAKE IS ASSOCIATED WITH HIGHER PERFORMANCE IN THE AIBL PACC SCORE IN COGNITIVELY NORMAL ADULTS: AUSTRALIAN IMAGING, BIOMARKERS AND LIFESTYLE (AIBL) STUDY. Alzheimer's and Dementia, 2018, 14, P1368.	0.4	0
167	O1â€04â€01: PRECLINICAL ALZHEIMER'S DISEASE IS ASSOCIATED WITH LEARNING IMPAIRMENTS OVER SIX DAYS: RESULTS FROM THE ONLINE REPEATED COGNITIVE ASSESSMENT (ORCA) STUDY. Alzheimer's and Dementia, 2018, 14, P223.	0.4	0
168	O2â€15â€03: DIFFERENTIAL RISK FACTORS FOR PROGRESSION TO MCI/DEMENCIA BY AMYLOIDâ€BETA STATUS. Alzheimer's and Dementia, 2018, 14, P661.	0.4	0
169	P1â€440: INCREASED CEREBRAL BLOOD FLOW WITH INCREASED AMYLOID BURDEN IN PRECLINICAL AD. Alzheimer's and Dementia, 2018, 14, P479.	0.4	0
170	ICâ€Pâ€008: VISUAL ASSESSMENT OF Î²â€AMYLOID PET SCAN IS IMPROVED BY CAPAIBL. Alzheimer's and Dementia, 2018, 14, P18.	0.4	0
171	P1â€006: EXAMINING THE RESILIENCE OF SUPERAGERS: RISK OF CLINICAL PROGRESSION AND AÎ²â€ASSOCIATED MEMORY DECLINE OVER 8 YEARS. Alzheimer's and Dementia, 2018, 14, P264.	0.4	0
172	Utility of an Alzheimerâ€™s Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimerâ€™s Disease: A Prospective Longitudinal Study. Journal of Alzheimer's Disease, 2018, 66, 1193-1211.	1.2	27
173	<scp>CSF</scp> progranulin increases in the course of Alzheimer's disease and is associated with <scp>STREM</scp> 2, neurodegeneration and cognitive decline. EMBO Molecular Medicine, 2018, 10, .	3.3	64
174	A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 423.	1.7	16
175	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nature Reviews Neurology, 2018, 14, 639-652.	4.9	434
176	A Framework to Objectively Identify Reference Regions for Normalizing Quantitative Imaging. Lecture Notes in Computer Science, 2018, , 65-72.	1.0	1
177	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimerâ€™s disease. Brain, 2018, 141, 3065-3080.	3.7	116
178	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1427-1437.	0.4	51
179	Mediterranean diet adherence and rate of cerebral AÎ²-amyloid accumulation: Data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Translational Psychiatry, 2018, 8, 238.	2.4	49
180	Relationship Between Amyloid-Î² Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1313-1325.	1.2	19

#	ARTICLE	IF	CITATIONS
181	Sex, amyloid, and <i>APOE</i> ϵ 4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. <i>Alzheimer's and Dementia</i> , 2018, 14, 1193-1203.	0.4	169
182	Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1299-1305.	1.2	28
183	Ocular Biomarkers of Alzheimer's Disease: The Role of Anterior Eye and Potential Future Directions. , 2018, 59, 3554.		22
184	Effect of <i>BDNF</i> Val66Met on disease markers in dominantly inherited Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 84, 424-435.	2.8	25
185	The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults. <i>Intelligence</i> , 2018, 70, 22-29.	1.6	13
186	Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 977-988.	1.2	15
187	Implementing the centiloid transformation for 11C-PiB and β 2-amyloid 18F-PET tracers using CapAIBL. <i>NeuroImage</i> , 2018, 183, 387-393.	2.1	94
188	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. <i>PLoS ONE</i> , 2018, 13, e0195838.	1.1	51
189	Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 70, 170-179.	1.5	14
190	Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimer's disease, mild cognitive impairment, and healthy aging: A longitudinal study.. <i>Psychological Assessment</i> , 2018, 30, 1308-1316.	1.2	5
191	Creutzfeldt-Jakob disease surveillance in Australia: update to December 2016. <i>Communicable Diseases Intelligence (2018)</i> , 2018, 42, .	0.3	0
192	Amyloid burden and incident depressive symptoms in cognitively normal older adults. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 455-463.	1.3	49
193	Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 441-446.	1.2	9
194	Cognitive impairment and decline in cognitively normal older adults with high amyloid β 2: A meta-analysis. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 108-121.	1.2	131
195	Selenium Levels in Serum, Red Blood Cells, and Cerebrospinal Fluid of Alzheimer's Disease Patients: A Report from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL). <i>Journal of Alzheimer's Disease</i> , 2017, 57, 183-193.	1.2	54
196	<i>APOE</i> ϵ 4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 411-422.	1.2	9
197	Plasma Amyloid β 2 Peptides in Type 2 Diabetes: A Matched Case-Control Study. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1127-1133.	1.2	14
198	Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 1197-1206.	0.4	45

#	ARTICLE	IF	CITATIONS
199	The $\epsilon 4$ Allele Is Associated with Lower Selenium Levels in the Brain: Implications for Alzheimer's Disease. ACS Chemical Neuroscience, 2017, 8, 1459-1464.	1.7	48
200	Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 60-72.	1.2	29
201	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. Scientific Reports, 2017, 7, 1225.	1.6	42
202	Characterization and Identification of Dityrosine Cross-Linked Peptides Using Tandem Mass Spectrometry. Analytical Chemistry, 2017, 89, 6136-6145.	3.2	70
203	Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals. Journal of Alzheimer's Disease, 2017, 58, 1293-1302.	1.2	35
204	A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: The preclinical AD consortium. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 147-155.	1.2	28
205	Biochemically-defined pools of amyloid- β in sporadic Alzheimer's disease: correlation with amyloid PET. Brain, 2017, 140, 1486-1498.	3.7	123
206	Increased Carbohydrate Intake is Associated with Poorer Performance in Verbal Memory and Attention in an APOE Genotype-Dependent Manner. Journal of Alzheimer's Disease, 2017, 58, 193-201.	1.2	12
207	Using Robust Normative Data to Investigate the Neuropsychology of Cognitive Aging. Archives of Clinical Neuropsychology, 2017, 32, 142-154.	0.3	51
208	A systemic view of Alzheimer disease " insights from amyloid- β metabolism beyond the brain. Nature Reviews Neurology, 2017, 13, 612-623.	4.9	581
209	Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 179-187.	1.2	129
210	A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β -amyloid load in an AD cohort. Scientific Reports, 2017, 7, 14057.	1.6	22
211	Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. Scientific Reports, 2017, 7, 9766.	1.6	59
212	BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF. International Psychogeriatrics, 2017, 29, 1825-1834.	0.6	21
213	A rigorous method to enrich for exosomes from brain tissue. Journal of Extracellular Vesicles, 2017, 6, 1348885.	5.5	218
214	[O3a€“09a€“01]: IMPLEMENTING THE CENTILOID TRANSFORMATION FOR ¹⁸ F-FLORBETABEN AND ¹⁸ F-NAV4694 USING CAPAIBL. Alzheimer's and Dementia, 2017, 13, P920.	0.4	1
215	A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 622-635.	1.8	59
216	Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms. Journal of Alzheimer's Disease, 2017, 61, 169-183.	1.2	21

#	ARTICLE	IF	CITATIONS
217	[P1â€“607]: SELFâ€REPORTED PHYSICAL ACTIVITY IS ASSOCIATED WITH TAU BURDEN AS MEASURED BY PET. Alzheimer's and Dementia, 2017, 13, P528.	0.4	0
218	A normalisation framework for quantitative brain imaging; application to quantitative susceptibility mapping. , 2017, , .		3
219	18F-Florbetaben PET beta-amyloid binding expressed in Centiloids. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2053-2059.	3.3	87
220	Amyloid Î²â€“associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 156-164.	1.2	19
221	The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinsonâ€™s disease. Acta Neuropathologica Communications, 2017, 5, 53.	2.4	77
222	Associations of neighborhood environment with brain imaging outcomes in the Australian Imaging, Biomarkers and Lifestyle cohort. Alzheimer's and Dementia, 2017, 13, 388-398.	0.4	23
223	AÎ²-amyloid and Tau Imaging in Dementia. Seminars in Nuclear Medicine, 2017, 47, 75-88.	2.5	96
224	Plasma Cortisol, Brain Amyloid-Î², and Cognitive Decline in Preclinical Alzheimerâ€™s Disease: A 6-Year Prospective Cohort Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 45-52.	1.1	32
225	[P2â€“535]: DIFFERENCES IN LONGEVITY AND DEATH CERTIFICATION ACCOUNT FOR SEX DISPARITY IN DEMENTIA MORTALITY RATES. Alzheimer's and Dementia, 2017, 13, P847.	0.4	0
226	[P3â€“224]: THE INFLUENCE OF LOWâ€DENSITY LIPOPROTEINS ON NEOCORTICAL AMYLOID LOAD IN THE AUSTRALIAN IMAGING BIOMARKER AND LIFESTYLE STUDY. Alzheimer's and Dementia, 2017, 13, P1023.	0.4	0
227	[P3â€“243]: A MASS SPECTROMETRYâ€BASED DISCOVERY AND REPLICATION OF A MULTIâ€ANALYTE CLASSIFIER FOR NEOCORTICAL AMYLOID PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P1033.	0.4	0
228	[P3â€“462]: CONSIDERATION OF PRECLINICAL AD FROM THE PERSPECTIVE OF NORMAL AGING: AMYLOIDâ€Î² RELATED CHANGES IN FLUID AND CRYSTALLIZED INTELLIGENCE IN A ROBUST SAMPLE OF HEALTHY OLDER ADULTS. Alzheimer's and Dementia, 2017, 13, P1150.	0.4	0
229	[P4â€“134]: INSULIN RESISTANCE IS ASSOCIATED WITH REDUCTIONS IN SPECIFIC COGNITIVE DOMAINS AND INCREASES IN CSF TAU IN COGNITIVELY NORMAL ADULTS. Alzheimer's and Dementia, 2017, 13, P1308.	0.4	0
230	[P4â€“136]: ILâ€10 AND ILâ€12/23P40 ARE JOINTLY ASSOCIATED AS PREDICTORS OF AÎ²â€AMYLOID LOAD IN A BROADER BLOODâ€BASED BIOMARKER PANEL. Alzheimer's and Dementia, 2017, 13, P1308.	0.4	0
231	[P4â€“255]: CORTICAL CEREBRAL MICROINFARCTS ON 3T MRI IN ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1378.	0.4	1
232	[P1â€“416]: CSF TOTAL TAU AS A BIOMARKER FOR NEURONAL INJURY IN ALZHEIMER'S DISEASE: ALIGNING RATES OF CSF CHANGE WITH RATES OF HIPPOCAMPAL AND CORTICAL GRAY MATTER ATROPHY. Alzheimer's and Dementia, 2017, 13, P436.	0.4	0
233	[P2â€“263]: GRAPHICAL NETWORK ANALYSES INFORMS PET AÎ²â€AMYLOID BIOMARKER DISCOVERY VIA QUANTIFICATION OF INDIVIDUAL PEPTIDE CONNECTIONS. Alzheimer's and Dementia, 2017, 13, P714.	0.4	0
234	[P1â€“444]: QUANTITATIVE SUSCEPTIBILITY MAPPING OF THE HIPPOCAMPUS PREDICTS HIPPOCAMPAL ATROPHY IN AÎ²+ ELDERLY CONTROLS AND ALZHEIMER'S DISEASE PATIENTS. Alzheimer's and Dementia, 2017, 13, P454.	0.4	2

#	ARTICLE	IF	CITATIONS
235	Cerebral quantitative susceptibility mapping predicts amyloid- β -related cognitive decline. <i>Brain</i> , 2017, 140, 2112-2119.	3.7	213
236	Evaluation of Cholinergic Deficiency in Preclinical Alzheimer's Disease Using Pupillometry. <i>Journal of Ophthalmology</i> , 2017, 2017, 1-8.	0.6	29
237	A Multi-Cohort Study of ApoE ϵ 4 and Amyloid- β Effects on the Hippocampus in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1159-1174.	1.2	36
238	Subjective Memory Complaints in APOE ϵ 4 Carriers are Associated with High Amyloid- β Burden. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 1115-1122.	1.2	45
239	Impact of Mild Head Injury on Neuropsychological Performance in Healthy Older Adults: Longitudinal Assessment in the AIBL Cohort. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 105.	1.7	13
240	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. <i>PLoS ONE</i> , 2016, 11, e0152082.	1.1	45
241	P4-388: XANAMEMTM : A Novel 11B-HSD1 Inhibitor with Potential to Provide Durable Symptomatic and Disease Modifying Benefits in Alzheimer's Disease. , 2016, 12, P1186-P1186.		1
242	β -related memory decline in <i>APOE</i> ϵ 4 noncarriers. <i>Neurology</i> , 2016, 86, 1635-1642.	1.5	37
243	Apolipoprotein C-II Adopts Distinct Structures in Complex with Micellar and Submicellar Forms of the Amyloid-Inhibiting Lipid-Mimetic Dodecylphosphocholine. <i>Biophysical Journal</i> , 2016, 110, 85-94.	0.2	4
244	β -Amyloid, APOE and BDNF Genotype, and Depressive and Anxiety Symptoms in Cognitively Normal Older Women and Men. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 1191-1195.	0.6	25
245	Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia. <i>Journal of Molecular Neuroscience</i> , 2016, 60, 362-370.	1.1	14
246	The Neurobiology and Age-Related Prevalence of the ϵ 4 Allele of Apolipoprotein E in Alzheimer's Disease Cohorts. <i>Journal of Molecular Neuroscience</i> , 2016, 60, 316-324.	1.1	82
247	<i>BDNF</i> Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. <i>Brain</i> , 2016, 139, 2766-2777.	3.7	70
248	A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2016, 60, 354-361.	1.1	37
249	Predicting Alzheimer disease from a blood-based biomarker profile. <i>Neurology</i> , 2016, 87, 1093-1101.	1.5	26
250	Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. <i>Lancet Neurology</i> , The, 2016, 15, 1044-1053.	4.9	175
251	Magnetic Resonance Imaging of Vascular Contributions to Cognitive Impairment and Dementia. <i>Journal of Molecular Neuroscience</i> , 2016, 60, 349-353.	1.1	9
252	Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2016, 132, 377-389.	3.9	40

#	ARTICLE	IF	CITATIONS
253	Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's disease. <i>Scientific Reports</i> , 2016, 6, 29078.	1.6	39
254	CapAIBL: Automated Reporting of Cortical PET Quantification Without Need of MRI on Brain Surface Using a Patch-Based Method. <i>Lecture Notes in Computer Science</i> , 2016, , 109-116.	1.0	6
255	Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). <i>Lancet Neurology</i> , The, 2016, 15, 1317-1325.	4.9	87
256	The Relationship between Sleep Quality and Brain Amyloid Burden. <i>Sleep</i> , 2016, 39, 1063-1068.	0.6	123
257	Rubidium and potassium levels are altered in Alzheimer's disease brain and blood but not in cerebrospinal fluid. <i>Acta Neuropathologica Communications</i> , 2016, 4, 119.	2.4	39
258	Laser ablation-inductively coupled plasma-mass spectrometry imaging of white and gray matter iron distribution in Alzheimer's disease frontal cortex. <i>NeuroImage</i> , 2016, 137, 124-131.	2.1	57
259	Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 2, 19-26.	1.2	72
260	Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 18-26.	1.2	30
261	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. <i>Annals of Neurology</i> , 2016, 79, 929-939.	2.8	381
262	Amyloid- β Peptide A β 23pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons. <i>Journal of Biological Chemistry</i> , 2016, 291, 6134-6145.	1.6	74
263	Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 796-804.	0.4	135
264	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. <i>Brain</i> , 2016, 139, 2528-2539.	3.7	58
265	High Content, Multi-Parameter Analyses in Buccal Cells to Identify Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2016, 13, 787-799.	0.7	23
266	Alzheimer's Disease and the Early Signs of Age-Related Macular Degeneration. <i>Current Alzheimer Research</i> , 2016, 13, 1259-1266.	0.7	42
267	Comparative analysis of the Cancer Council of Victoria and the online Commonwealth Scientific and Industrial Research Organisation FFQ. <i>British Journal of Nutrition</i> , 2015, 114, 1683-1693.	1.2	5
268	Alzheimer's disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15056.	18.1	1,210
269	Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer's disease.. <i>Neuropsychology</i> , 2015, 29, 571-581.	1.0	43
270	Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in β PET Amyloid- β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 175-187.	1.2	47

#	ARTICLE	IF	CITATIONS
271	Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimer's Disease Risk. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 443-452.	1.2	7
272	Peripheral β -Defensins 1 and 2 are Elevated in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 1131-1143.	1.2	15
273	Alterations in dorsal and ventral posterior cingulate connectivity in APOE ϵ 4 carriers at risk of Alzheimer's disease. <i>BJPsych Open</i> , 2015, 1, 139-148.	0.3	5
274	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 1079-1089.	1.2	28
275	A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 50.	3.0	10
276	Alzheimer's disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 71.	3.0	14
277	Semi-automated hippocampal segmentation in people with cognitive impairment using an age appropriate template for registration. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 1631-1638.	1.9	9
278	Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?1. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 815-843.	1.2	84
279	Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ϵ 4 and Is Detectable over 18-Months. <i>PLoS ONE</i> , 2015, 10, e0139082.	1.1	22
280	Factors Associated With the Onset and Persistence of Post-Lumbar Puncture Headache. <i>JAMA Neurology</i> , 2015, 72, 325.	4.5	59
281	O3-03-04: Characteristics of the neighborhood built environment are associated with MRI brain volumetric and amyloid beta burden measures: Findings from the australian imaging, biomarkers, and lifestyle (AIBL) study. , 2015, 11, P223-P225.		0
282	Bayesian Graphical Network Analyses Reveal Complex Biological Interactions Specific to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 917-925.	1.2	13
283	Reduction of p75 neurotrophin receptor ameliorates the cognitive deficits in a model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 740-752.	1.5	25
284	Decreased Plasma Iron in Alzheimer's Disease Is Due to Transferrin Desaturation. <i>ACS Chemical Neuroscience</i> , 2015, 6, 398-402.	1.7	75
285	APOE ϵ 4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1239-1244.	1.5	75
286	Comparison of MR-less PiB SUVR quantification methods. <i>Neurobiology of Aging</i> , 2015, 36, S159-S166.	1.5	96
287	High Order W_{O2} -Reactive Stable Oligomers of Amyloid- β are Produced in vivo and in vitro via Dialysis and Filtration of Synthetic Amyloid- β Monomer. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 69-78.	1.2	2
288	Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. <i>Brain</i> , 2015, 138, 1036-1045.	3.7	67

#	ARTICLE	IF	CITATIONS
289	Stabilization of Nontoxic A β -Oligomers: Insights into the Mechanism of Action of Hydroxyquinolines in Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2015, 35, 2871-2884.	1.7	67
290	Relationships Between Performance on the Cogstate Brief Battery, Neurodegeneration, and A β Accumulation in Cognitively Normal Older Adults and Adults with MCI. <i>Archives of Clinical Neuropsychology</i> , 2015, 30, 49-58.	0.3	40
291	Longitudinal cognitive decline in the AIBL cohort: The role of APOE ϵ 4 status. <i>Neuropsychologia</i> , 2015, 75, 411-419.	0.7	27
292	Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. <i>Neurobiology of Aging</i> , 2015, 36, 1231-1238.	1.5	71
293	Amyloid- β , Anxiety, and Cognitive Decline in Preclinical Alzheimer Disease. <i>JAMA Psychiatry</i> , 2015, 72, 284.	6.0	160
294	Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 16.	3.0	22
295	Glycosaminoglycan sulfation determines the biochemical properties of prion protein aggregates. <i>Glycobiology</i> , 2015, 25, 745-755.	1.3	12
296	Small angle X-ray scattering analysis of Cu ²⁺ -induced oligomers of the Alzheimer's amyloid β peptide. <i>Metallomics</i> , 2015, 7, 536-543.	1.0	25
297	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2015, 85, 790-798.	1.5	27
298	Enduring Elevations of Hippocampal Amyloid Precursor Protein and Iron Are Features of β -Amyloid Toxicity and Are Mediated by Tau. <i>Neurotherapeutics</i> , 2015, 12, 862-873.	2.1	50
299	Traumatic brain injury induces elevation of Co in the human brain. <i>Metallomics</i> , 2015, 7, 66-70.	1.0	11
300	Tau imaging: early progress and future directions. <i>Lancet Neurology</i> , The, 2015, 14, 114-124.	4.9	432
301	A β imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 431-436.	0.9	78
302	Alpha-synuclein oligomers and fibrils originate in two distinct conformer pools: a small angle X-ray scattering and ensemble optimisation modelling study. <i>Molecular BioSystems</i> , 2015, 11, 190-196.	2.9	24
303	MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET. <i>PLoS ONE</i> , 2014, 9, e84777.	1.1	43
304	Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer's Disease: A Preliminary Study. <i>PLoS ONE</i> , 2014, 9, e86498.	1.1	75
305	Cerebral Microbleeds: A Review of Clinical, Genetic, and Neuroimaging Associations. <i>Frontiers in Neurology</i> , 2014, 4, 205.	1.1	176
306	C-terminal peptides modelling constitutive PrPC processing demonstrate ameliorated toxicity predisposition consequent to κ -cleavage. <i>Biochemical Journal</i> , 2014, 459, 103-115.	1.7	11

#	ARTICLE	IF	CITATIONS
307	Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study. <i>British Journal of Psychiatry</i> , 2014, 204, 400-401.	1.7	29
308	Shaken, Not Sonicated?. <i>New England Journal of Medicine</i> , 2014, 371, 571-572.	13.9	1
309	Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease. <i>Science Translational Medicine</i> , 2014, 6, 226ra30.	5.8	320
310	Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). <i>International Psychogeriatrics</i> , 2014, 26, 543-554.	0.6	37
311	Incidence of cerebral microbleeds in preclinical Alzheimer disease. <i>Neurology</i> , 2014, 82, 1266-1273.	1.5	125
312	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1111.	4.5	112
313	Autobiographical narratives relate to Alzheimer's disease biomarkers in older adults. <i>International Psychogeriatrics</i> , 2014, 26, 1737-1746.	0.6	9
314	Guanidine hydrochloride denaturation of dopamine-induced α -synuclein oligomers: A small-angle X-ray scattering study. <i>Proteins: Structure, Function and Bioinformatics</i> , 2014, 82, 10-21.	1.5	9
315	Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. <i>Brain</i> , 2014, 137, 1762-1771.	3.7	234
316	Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. <i>Brain</i> , 2014, 137, 221-231.	3.7	182
317	The landscape of ageing—insights from AD imaging markers. <i>Nature Reviews Neurology</i> , 2014, 10, 678-679.	4.9	11
318	Decreased serum zinc is an effect of ageing and not Alzheimer's disease. <i>Metallomics</i> , 2014, 6, 1216-1219.	1.0	34
319	The effect of paraformaldehyde fixation and sucrose cryoprotection on metal concentration in murine neurological tissue. <i>Journal of Analytical Atomic Spectrometry</i> , 2014, 29, 565-570.	1.6	45
320	An iron-dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta. <i>Chemical Science</i> , 2014, 5, 2160-2169.	3.7	98
321	Influence of <i>BDNF</i> Val66Met on the relationship between physical activity and brain volume. <i>Neurology</i> , 2014, 83, 1345-1352.	1.5	58
322	In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 816-826.	3.3	156
323	Oral Treatment with Cull(atSm) Increases Mutant SOD1 In Vivo but Protects Motor Neurons and Improves the Phenotype of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. <i>Journal of Neuroscience</i> , 2014, 34, 8021-8031.	1.7	161
324	Among Vitamin B12 Deficient Older People, High Folate Levels are Associated with Worse Cognitive Function: Combined Data from Three Cohorts. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 661-668.	1.2	76

#	ARTICLE	IF	CITATIONS
325	Symptom onset in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2014, 83, 253-260.	1.5	391
326	Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment Strategies. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 499.	2.0	70
327	A β and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 743.	0.4	66
328	An increased neutrophil α lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation. <i>Journal of Neuroimmunology</i> , 2014, 273, 65-71.	1.1	87
329	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 53-61.	0.4	114
330	Plasma Amyloid- β Levels are Significantly Associated with a Transition Toward Alzheimer's Disease as Measured by Cognitive Decline and Change in Neocortical Amyloid Burden. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 95-104.	1.2	41
331	Amyloid- β Related Memory Decline is not Associated with Subjective or Informant Rated Cognitive Impairment in Healthy Adults. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 677-686.	1.2	63
332	Personal Memory Function in Mild Cognitive Impairment and Subjective Memory Complaints: Results from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 551-561.	1.2	10
333	¹⁸ F-florbetaben A β imaging in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 4.	3.0	49
334	Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes. <i>Biomarkers in Medicine</i> , 2013, 7, 641-662.	0.6	30
335	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4502-9.	3.3	309
336	Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. <i>BMC Psychology</i> , 2013, 1, 30.	0.9	153
337	Predicting Alzheimer disease with β amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing. <i>Annals of Neurology</i> , 2013, 74, 905-913.	2.8	194
338	Profiling the iron, copper and zinc content in primary neuron and astrocyte cultures by rapid online quantitative size exclusion chromatography-inductively coupled plasma-mass spectrometry. <i>Metallomics</i> , 2013, 5, 1656.	1.0	39
339	Longitudinal Analysis of Serum Copper and Ceruloplasmin in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 171-182.	1.2	46
340	A β amyloid, cognition, and APOE genotype in healthy older adults. <i>Alzheimer's and Dementia</i> , 2013, 9, 538-545.	0.4	51
341	Research and standardization in Alzheimer's trials: Reaching international consensus. , 2013, 9, 160-168.		20
342	Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 357-367.	4.9	1,738

#	ARTICLE	IF	CITATIONS
343	Mixed Ligand Cu ²⁺ -Complexes of a Model Therapeutic with Alzheimer's Amyloid- β Peptide and Monoamine Neurotransmitters. <i>Inorganic Chemistry</i> , 2013, 52, 4303-4318.	1.9	54
344	BDNF Val66Met, A β amyloid, and cognitive decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2457-2464.	1.5	109
345	Cross-sectional and Longitudinal Analysis of the Relationship Between A β Deposition, Cortical Thickness, and Memory in Cognitively Unimpaired Individuals and in Alzheimer Disease. <i>JAMA Neurology</i> , 2013, 70, 903.	4.5	170
346	Development of a Platinum Complex as an anti-Amyloid Agent for the Therapy of Alzheimer's Disease. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 3374-3378.	7.2	56
347	Decline in Cognitive Function over 18 Months in Healthy Older Adults with High Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2013, 34, 861-871.	1.2	42
348	Lack of reliable evidence for a distinctive β -related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study. <i>Brain</i> , 2013, 136, 2201-2216.	3.7	28
349	The pattern of atrophy in familial Alzheimer disease. <i>Neurology</i> , 2013, 81, 1425-1433.	1.5	67
350	Three-Month Stability of the CogState Brief Battery in Healthy Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease: Results from the Australian Imaging, Biomarkers, and Lifestyle-Rate of Change Substudy (AIBL-ROCS). <i>Archives of Clinical Neuropsychology</i> , 2013, 28, 320-330.	0.3	90
351	Head-to-Head Comparison of ¹¹ C-PiB and ¹⁸ F-AZD4694 (NAV4694) for β -Amyloid Imaging in Aging and Dementia. <i>Journal of Nuclear Medicine</i> , 2013, 54, 880-886.	2.8	145
352	The association of A β amyloid and composite cognitive measures in healthy older adults and MCI. <i>International Psychogeriatrics</i> , 2013, 25, 1667-1677.	0.6	24
353	Cognitive Decline in Adults with Amnesic Mild Cognitive Impairment and High Amyloid- β : Prodromal Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 1167-1176.	1.2	34
354	Cognitive consequences of high A β amyloid in mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimer's disease.. <i>Neuropsychology</i> , 2013, 27, 322-332.	1.0	33
355	Rapid Decline in Episodic Memory in Healthy Older Adults with High Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2013, 33, 675-679.	1.2	62
356	Pupil Response Biomarkers Distinguish Amyloid Precursor Protein Mutation Carriers from Non-Carriers. <i>Current Alzheimer Research</i> , 2013, 10, 790-796.	0.7	30
357	Decreased Copper in Alzheimer's Disease Brain Is Predominantly in the Soluble Extractable Fraction. <i>International Journal of Alzheimer's Disease</i> , 2013, 2013, 1-7.	1.1	36
358	Pupil Response Biomarkers for Early Detection and Monitoring of Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2013, 10, 931-939.	0.7	26
359	Ammonium hydroxide treatment of A β produces an aggregate free solution suitable for biophysical and cell culture characterization. <i>PeerJ</i> , 2013, 1, e73.	0.9	93
360	The Animal Models of Dementia and Alzheimer's Disease for Pre-Clinical Testing and Clinical Translation. <i>Current Alzheimer Research</i> , 2012, 9, 1010-1029.	0.7	34

#	ARTICLE	IF	CITATIONS
361	Relationship between Memory Performance and β -Amyloid Deposition at Different Stages of Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2012, 10, 141-144.	0.8	43
362	Developing an international network for Alzheimer's research: the Dominantly Inherited Alzheimer Network. <i>Clinical Investigation</i> , 2012, 2, 975-984.	0.0	180
363	Regional dynamics of amyloid- β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. <i>Brain</i> , 2012, 135, 2126-2139.	3.7	222
364	The Prion Protein Preference of Sporadic Creutzfeldt-Jakob Disease Subtypes. <i>Journal of Biological Chemistry</i> , 2012, 287, 36465-36472.	1.6	9
365	Stronger effect of amyloid load than <i>APOE</i> genotype on cognitive decline in healthy older adults. <i>Neurology</i> , 2012, 79, 1645-1652.	1.5	96
366	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2012, 367, 795-804.	13.9	3,005
367	Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 1318.	4.9	348
368	Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 345-358.	0.8	111
369	The hypoxia imaging agent Cull(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease. <i>Journal of Experimental Medicine</i> , 2012, 209, 837-854.	4.2	151
370	In vitro characterization of [^{18}F]-florbetaben, an $\text{A}\beta$ imaging radiotracer. <i>Nuclear Medicine and Biology</i> , 2012, 39, 1042-1048.	0.3	54
371	Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: The AIBL Active trial. <i>BMC Psychiatry</i> , 2012, 12, 167.	1.1	40
372	Utility of an improved model of amyloid-beta ($\text{A}\beta$ 1-42) toxicity in <i>Caenorhabditis elegans</i> for drug screening for Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2012, 7, 57.	4.4	188
373	Variability in Blood-Based Amyloid- β Assays: The Need for Consensus on Pre-Analytical Processing. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 323-336.	1.2	30
374	Comparison of ^{11}C -PiB and ^{18}F -florbetaben for $\text{A}\beta$ imaging in ageing and Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 983-989.	3.3	161
375	The role of metallobiology and amyloid- β peptides in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2012, 120, 149-166.	2.1	233
376	Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer's disease. <i>Journal of Neuroscience Methods</i> , 2012, 205, 96-109.	1.3	17
377	Homocysteine, Vitamin B12, and Folic Acid Levels in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: Baseline Characteristics in Subjects of the Australian Imaging Biomarker Lifestyle Study. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 909-922.	1.2	83
378	Independent contribution of temporal β -amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. <i>Brain</i> , 2011, 134, 798-807.	3.7	132

#	ARTICLE	IF	CITATIONS
379	Investigation of Matrix Metalloproteinases, MMP-2 and MMP-9, in Plasma Reveals a Decrease of MMP-2 in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 779-786.	1.2	49
380	iatrogenic Creutzfeldtâ€“Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients?. <i>Medical Journal of Australia</i> , 2011, 194, 214-215.	0.8	0
381	Increasing the Predictive Accuracy of Amyloid- β^2 Blood-Borne Biomarkers in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 47-59.	1.2	16
382	The Alzheimerâ€™s therapeutic PBT2 promotes amyloidâ€™ degradation and GSK3 phosphorylation via a metal chaperone activity. <i>Journal of Neurochemistry</i> , 2011, 119, 220-230.	2.1	167
383	Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study. <i>Neuropsychologia</i> , 2011, 49, 2384-2390.	0.7	139
384	Longitudinal assessment of A β^2 and cognition in aging and Alzheimer disease. <i>Annals of Neurology</i> , 2011, 69, 181-192.	2.8	730
385	Copper Promotes the Trafficking of the Amyloid Precursor Protein. <i>Journal of Biological Chemistry</i> , 2011, 286, 8252-8262.	1.6	90
386	Crystal Structure of the Amyloid- β^2 p3 Fragment Provides a Model for Oligomer Formation in Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2011, 31, 1419-1426.	1.7	99
387	Amyloid Imaging with ¹⁸ F-Florbetaben in Alzheimer Disease and Other Dementias. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1210-1217.	2.8	311
388	Relationship between atrophy and β^2 -amyloid deposition in Alzheimer disease. <i>Annals of Neurology</i> , 2010, 67, 317-324.	2.8	322
389	Plasma Amyloid- β^2 as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 1233-1242.	1.2	122
390	PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 509-516.	1.2	347
391	The structure of dopamine induced β^2 -synuclein oligomers. <i>European Biophysics Journal</i> , 2010, 39, 1407-1419.	1.2	87
392	Glycosaminoglycan Sulphation Affects the Seeded Misfolding of a Mutant Prion Protein. <i>PLoS ONE</i> , 2010, 5, e12351.	1.1	21
393	Larger temporal volume in elderly with high versus low beta-amyloid deposition. <i>Brain</i> , 2010, 133, 3349-3358.	3.7	130
394	Iron-Export Ferroxidase Activity of β^2 -Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease. <i>Cell</i> , 2010, 142, 857-867.	13.5	597
395	Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. <i>Neurobiology of Aging</i> , 2010, 31, 1275-1283.	1.5	885
396	Blood-Borne Amyloid- β^2 Dimer Correlates with Clinical Markers of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2010, 30, 6315-6322.	1.7	70

#	ARTICLE	IF	CITATIONS
397	Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2010, 6, 291-296.	0.4	53
398	Alzheimer's A β Peptides with Disease-Associated N-Terminal Modifications: Influence of Isomerisation, Truncation and Mutation on Cu ²⁺ Coordination. <i>PLoS ONE</i> , 2010, 5, e15875.	1.1	40
399	Paradoxical Condensation of Copper with Elevated β -Amyloid in Lipid Rafts under Cellular Copper Deficiency Conditions. <i>Journal of Biological Chemistry</i> , 2009, 284, 21899-21907.	1.6	55
400	The <i>Caenorhabditis elegans</i> A β ¹⁻⁴² Model of Alzheimer Disease Predominantly Expresses A β ³⁻⁴² . <i>Journal of Biological Chemistry</i> , 2009, 284, 22697-22702.	1.6	108
401	High Striatal Amyloid β -Peptide Deposition Across Different Autosomal Alzheimer Disease Mutation Types. <i>Archives of Neurology</i> , 2009, 66, 1537-44.	4.9	156
402	Formation of dopamine-mediated β -synuclein-soluble oligomers requires methionine oxidation. <i>Free Radical Biology and Medicine</i> , 2009, 46, 1328-1337.	1.3	104
403	Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 1213-1221.	1.0	133
404	Restored degradation of the Alzheimer's amyloid β peptide by targeting amyloid formation. <i>Journal of Neurochemistry</i> , 2009, 108, 1198-1207.	2.1	85
405	Alanine-2 Carbonyl is an Oxygen Ligand in Cu ²⁺ Coordination of Alzheimer's Disease Amyloid- β Peptide: Relevance to N-Terminally Truncated Forms. <i>Journal of the American Chemical Society</i> , 2009, 131, 8760-8761.	6.6	163
406	Pleomorphic Copper Coordination by Alzheimer's Disease Amyloid- β Peptide. <i>Journal of the American Chemical Society</i> , 2009, 131, 1195-1207.	6.6	228
407	The ART of Loss: A β Imaging in the Evaluation of Alzheimer's Disease and other Dementias. <i>Molecular Neurobiology</i> , 2008, 38, 1-15.	1.9	94
408	The solubility of β -synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. <i>Journal of Neurochemistry</i> , 2008, 76, 87-96.	2.1	196
409	Exacerbation of Copper Toxicity in Primary Neuronal Cultures Depleted of Cellular Glutathione. <i>Journal of Neurochemistry</i> , 2008, 72, 2092-2098.	2.1	79
410	Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. <i>Lancet Neurology</i> , The, 2008, 7, 129-135.	4.9	631
411	Safety, efficacy, and biomarker findings of PBT2 in targeting A β as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2008, 7, 779-786.	4.9	657
412	Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial A β . <i>Neuron</i> , 2008, 59, 43-55.	3.8	629
413	Mechanisms of A β mediated neurodegeneration in Alzheimer's disease. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 181-198.	1.2	220
414	Mouse-adapted sporadic human Creutzfeldt-Jakob disease prions propagate in cell culture. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 2793-2801.	1.2	59

#	ARTICLE	IF	CITATIONS
415	Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. <i>NeuroImage</i> , 2008, 43, 430-439.	2.1	81
416	Automated 11C-PiB Standardized Uptake Value Ratio. <i>Academic Radiology</i> , 2008, 15, 1376-1389.	1.3	24
417	Cu ²⁺ Binding Modes of Recombinant β -Synuclein β Insights from EPR Spectroscopy. <i>Journal of the American Chemical Society</i> , 2008, 130, 7766-7773.	6.6	100
418	<i>In Vitro</i> Characterization of Pittsburgh Compound-B Binding to Lewy Bodies. <i>Journal of Neuroscience</i> , 2007, 27, 10365-10371.	1.7	154
419	β -amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. <i>Brain</i> , 2007, 130, 2837-2844.	3.7	739
420	Evaluating Atypical Dementia Syndromes Using Positron Emission Tomography With Carbon 11 ¹⁴ C-Labeled Pittsburgh Compound B. <i>Archives of Neurology</i> , 2007, 64, 1140.	4.9	72
421	Concentration Dependent Cu ²⁺ -Induced Aggregation and Dityrosine Formation of the Alzheimer's Disease Amyloid- β Peptide. <i>Biochemistry</i> , 2007, 46, 2881-2891.	1.2	179
422	Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the β amyloid pathway. <i>Brain</i> , 2006, 129, 2823-2839.	3.7	141
423	Pathways to the discovery of the β amyloid of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 155-161.	1.2	20
424	Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. <i>Journal of Neurochemistry</i> , 2006, 97, 1700-1725.	2.1	206
425	Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn ²⁺ complexes in Alzheimer's disease. <i>Aging Cell</i> , 2006, 5, 69-79.	3.0	74
426	Overexpression of β is associated with acceleration of onset of motor impairment and superoxide dismutase 1 aggregation in an amyotrophic lateral sclerosis mouse model. <i>Aging Cell</i> , 2006, 5, 153-165.	3.0	37
427	Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: Implications for Alzheimer β -amyloid pathology. <i>Journal of Inorganic Biochemistry</i> , 2006, 100, 952-962.	1.5	93
428	Degradation of the Alzheimer Disease Amyloid β -Peptide by Metal-dependent Up-regulation of Metalloprotease Activity. <i>Journal of Biological Chemistry</i> , 2006, 281, 17670-17680.	1.6	267
429	Copper-mediated Amyloid- β Toxicity Is Associated with an Intermolecular Histidine Bridge*. <i>Journal of Biological Chemistry</i> , 2006, 281, 15145-15154.	1.6	170
430	Dopamine promotes β -synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. <i>FASEB Journal</i> , 2005, 19, 1377-1379.	0.2	239
431	Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease β -amyloid. <i>FASEB Journal</i> , 2004, 18, 1427-1429.	0.2	251
432	Interaction of the Molecular Chaperone β -Crystallin with β -Synuclein: Effects on Amyloid Fibril Formation and Chaperone Activity. <i>Journal of Molecular Biology</i> , 2004, 340, 1167-1183.	2.0	198

#	ARTICLE	IF	CITATIONS
433	Methionine oxidation: Implications for the mechanism of toxicity of the β -amyloid peptide from Alzheimer's disease. <i>International Journal of Peptide Research and Therapeutics</i> , 2003, 10, 413-417.	0.1	13
434	Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. <i>Journal of Neuroscience Research</i> , 2003, 74, 386-392.	1.3	142
435	Methionine oxidation: Implications for the mechanism of toxicity of the β -amyloid peptide from Alzheimer's disease. <i>International Journal of Peptide Research and Therapeutics</i> , 2003, 10, 413-417.	0.9	6
436	Cytosolic β -amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. <i>Lancet, The</i> , 2003, 361, 1258-1265.	6.3	323
437	Neurotoxic, Redox-competent Alzheimer's β -Amyloid Is Released from Lipid Membrane by Methionine Oxidation. <i>Journal of Biological Chemistry</i> , 2003, 278, 42959-42965.	1.6	176
438	Metalloenzyme-like Activity of Alzheimer's Disease β -Amyloid. <i>Journal of Biological Chemistry</i> , 2002, 277, 40302-40308.	1.6	536
439	Annual Review of Gerontology and Geriatrics, Vol. 21. Vincent J. Cristofalo, Richard Adelman, and K. Warner Schaie (Eds.). New York: Springer Publishing Company, 2002, 296 pp., \$US 58.00 (hardcover).. <i>International Psychogeriatrics</i> , 2002, 14, 428-429.	0.6	0
440	Alzheimer's disease amyloid beta and prion protein amyloidogenic peptides promote macrophage survival, DNA synthesis and enhanced proliferative response to CSF-1 (M-CSF). <i>Brain Research</i> , 2002, 940, 49-54.	1.1	17
441	Intracellular Accumulation of Detergent-Soluble Amyloidogenic β Fragment of Alzheimer's Disease Precursor Protein in the Hippocampus of Aged Transgenic Mice. <i>Journal of Neurochemistry</i> , 2002, 72, 2479-2487.	2.1	74
442	Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β -Amyloid Accumulation in Alzheimer's Disease Transgenic Mice. <i>Neuron</i> , 2001, 30, 665-676.	3.8	1,419
443	Alzheimer's Disease Amyloid- β Binds Copper and Zinc to Generate an Allosterically Ordered Membrane-penetrating Structure Containing Superoxide Dismutase-like Subunits. <i>Journal of Biological Chemistry</i> , 2001, 276, 20466-20473.	1.6	595
444	Henryk M. Wisniewski and the amyloid theory of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2001, 3, 83-86.	1.2	4
445	The emerging European epidemic of variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy: lessons for Australia. <i>Medical Journal of Australia</i> , 2001, 174, 160-161.	0.8	2
446	Proteolytic Fragments of Alzheimer's Disease-Associated Presenilin 1 Are Present in Synaptic Organelles and Growth Cone Membranes of Rat Brain. <i>Journal of Neurochemistry</i> , 2001, 72, 1564-1573.	2.1	54
447	Interaction of linear homologous DNA duplexes via Holliday junction formation. <i>FEBS Journal</i> , 2001, 268, 7-14.	0.2	18
448	The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from β -secretase. <i>FEBS Journal</i> , 2001, 268, 5329-5336.	0.2	116
449	Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106-126. <i>Journal of Neuroscience Research</i> , 2001, 65, 565-572.	1.3	47
450	Variable phenotype of Alzheimer's disease with spastic paraparesis. <i>Annals of Neurology</i> , 2001, 49, 125-129.	2.8	90

#	ARTICLE	IF	CITATIONS
451	Crystal Structure of the N-terminal Heparin-Binding Domain of Alzheimer's Amyloid Precursor Protein. <i>Biochemical Society Transactions</i> , 2000, 28, A447-A447.	1.6	0
452	A β peptides and calcium influence secretion of the amyloid protein precursor from chick sympathetic neurons in culture. <i>Journal of Neuroscience Research</i> , 2000, 61, 449-457.	1.3	12
453	Amyloidogenicity and neurotoxicity of peptides corresponding to the helical regions of PrPC. <i>Journal of Neuroscience Research</i> , 2000, 62, 293-301.	1.3	53
454	Novel Leu723Pro amyloid precursor protein mutation increases amyloid β (43) peptide levels and induces apoptosis. <i>Annals of Neurology</i> , 2000, 47, 249-253.	2.8	82
455	Substrate-Bound β -Amyloid Peptides Inhibit Cell Adhesion and Neurite Outgrowth in Primary Neuronal Cultures. <i>Journal of Neurochemistry</i> , 2000, 74, 1122-1130.	2.1	47
456	β peptides and calcium influence secretion of the amyloid protein precursor from chick sympathetic neurons in culture. , 2000, 61, 449.		1
457	Amyloid Nomenclature Committee. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1999, 6, 151-151.	1.4	2
458	Amyloid precursor protein of Alzheimer's disease: evidence for a stable, full-length, trans-membrane pool in primary neuronal cultures. <i>European Journal of Neuroscience</i> , 1999, 11, 1779-1788.	1.2	24
459	The amyloid beta-protein precursor of Alzheimer's disease is degraded extracellularly by a Kunitz protease inhibitor domain-sensitive trypsin-like serine protease in cultures of chick sympathetic neurons. <i>FEBS Journal</i> , 1999, 266, 509-516.	0.2	15
460	Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. <i>Nature Structural Biology</i> , 1999, 6, 327-331.	9.7	229
461	Title is missing!. <i>International Journal of Peptide Research and Therapeutics</i> , 1999, 6, 129-134.	0.1	0
462	The synthesis and spectroscopic analysis of the neurotoxic prion peptide 106-126: Comparative use of manual Boc and Fmoc chemistry. <i>International Journal of Peptide Research and Therapeutics</i> , 1999, 6, 129-134.	0.1	10
463	Irregular distribution of cytochrome c oxidase protein subunits in aging and Alzheimer's disease. <i>Annals of Neurology</i> , 1999, 46, 656-660.	2.8	58
464	Soluble pool of A β amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. <i>Annals of Neurology</i> , 1999, 46, 860-866.	2.8	1,721
465	Analysis of presenilin 1 and presenilin 2 expression and processing by newly developed monoclonal antibodies. <i>Journal of Neuroscience Research</i> , 1999, 56, 405-419.	1.3	20
466	Familial Prion Disease Mutation Alters the Secondary Structure of Recombinant Mouse Prion Protein: Implications for the Mechanism of Prion Formation. <i>Biochemistry</i> , 1999, 38, 3280-3284.	1.2	35
467	Non- β Component of Alzheimer's Disease Amyloid (NAC) Revisited. <i>American Journal of Pathology</i> , 1999, 155, 1173-1181.	1.9	173
468	Copper inhibits β -amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion. <i>Biochemical Journal</i> , 1999, 344, 461-467.	1.7	158

#	ARTICLE	IF	CITATIONS
469	The amyloid precursor protein of Alzheimer disease in human brain and blood. <i>Journal of Leukocyte Biology</i> , 1999, 66, 567-574.	1.5	73
470	Soluble pool of A β amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. , 1999, 46, 860.		5
471	Effects of the amyloid protein precursor of Alzheimer's disease and other ligands of the LDL receptor-related protein on neurite outgrowth from sympathetic neurons in culture. <i>FEBS Letters</i> , 1998, 428, 13-16.	1.3	28
472	Subcellular localization of the Alzheimer's disease amyloid precursor protein and derived polypeptides expressed in a recombinant yeast system. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1998, 5, 79-89.	1.4	13
473	Copper-Binding Amyloid Precursor Protein Undergoes a Site-Specific Fragmentation in the Reduction of Hydrogen Peroxide. <i>Biochemistry</i> , 1998, 37, 7224-7230.	1.2	128
474	Mutations in the Transmembrane Domain of APP Altering β -Secretase Specificity. <i>Biochemistry</i> , 1997, 36, 15396-15403.	1.2	102
475	Expression and analysis of heparin-binding regions of the amyloid precursor protein of Alzheimer's disease. <i>FEBS Letters</i> , 1997, 415, 303-307.	1.3	48
476	Distinct sites of intracellular production for Alzheimer's disease A β 40/42 amyloid peptides. <i>Nature Medicine</i> , 1997, 3, 1016-1020.	15.2	716
477	The ins and outs of amyloid- β . <i>Nature</i> , 1997, 389, 677-678.	13.7	46
478	Tracking turncoat prion proteins. <i>Nature</i> , 1997, 388, 228-229.	13.7	8
479	Clues to the Etiology of Alzheimer's Disease Through the Study of the Amyloid Precursor Protein. <i>Brain Pathology</i> , 1997, 7, 1037-1037.	2.1	0
480	Human Amyloid Precursor-Like Protein 1. cDNA Cloning, Ectopic Expression in COS-7 Cells and Identification of Soluble Forms in the Cerebrospinal Fluid. <i>FEBS Journal</i> , 1997, 250, 354-363.	0.2	55
481	Collection and normal levels of the amyloid precursor protein in plasma. <i>Annals of Neurology</i> , 1997, 41, 121-124.	2.8	21
482	Alzheimer's disease-associated presenilin 1 in neuronal cells: Evidence for localization to the endoplasmic reticulum-Golgi intermediate compartment. , 1997, 49, 719-731.		68
483	Identification of Heparin-Binding Domains in the Amyloid Precursor Protein of Alzheimer's Disease by Deletion Mutagenesis and Peptide Mapping. <i>Journal of Neurochemistry</i> , 1997, 68, 1164-1172.	2.1	66
484	The Amyloid β -Protein of Alzheimer's Disease Increases Acetylcholinesterase Expression by Increasing Intracellular Calcium in Embryonal Carcinoma P19 Cells. <i>Journal of Neurochemistry</i> , 1997, 69, 1177-1184.	2.1	112
485	Alzheimer's disease-associated presenilin 1 in neuronal cells: Evidence for localization to the endoplasmic reticulum-Golgi intermediate compartment. , 1997, 49, 719.		5
486	Rapid cellular uptake of Alzheimer amyloid β A4 peptide by cultured human neuroblastoma cells. <i>FEBS Letters</i> , 1996, 394, 174-178.	1.3	48

#	ARTICLE	IF	CITATIONS
487	Iatrogenic and zoonotic Creutzfeldt-Jakob disease: the Australian perspective. Medical Journal of Australia, 1996, 164, 598-602.	0.8	19
488	Amyloid, aluminium and the aetiology of Alzheimer's disease. Medical Journal of Australia, 1996, 164, 383-383.	0.8	1
489	Tangle disentanglement. Nature, 1996, 383, 476-477.	13.7	23
490	Analysis of Heterogeneous β A4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay. Journal of Biological Chemistry, 1996, 271, 22908-22914.	1.6	461
491	The Nosology of Creutzfeldt-Jakob Disease and Conditions Related to the Accumulation of PrP ^{CJD} in the Nervous System. Brain Pathology, 1995, 5, 33-41.	2.1	82
492	Characterization of the high affinity heparin binding site of the Alzheimer's disease β A4 amyloid precursor protein (APP) and its enhancement by zinc(II). Journal of Molecular Recognition, 1995, 8, 247-257.	1.1	57
493	A synthetic substrate assay for the gamma-secretase of the β -A4 amyloid of alzheimer's disease. Journal of Peptide Science, 1995, 1, 132-139.	0.8	2
494	Amyloid, aluminium and the aetiology of Alzheimer's disease. Medical Journal of Australia, 1995, 163, 256-259.	0.8	29
495	Gelatinase A possesses a β -secretase-like activity in cleaving the amyloid protein precursor of Alzheimer's disease. FEBS Letters, 1995, 377, 267-270.	1.3	43
496	Catching the culprit prion. Nature, 1994, 370, 419-420.	13.7	17
497	The β A4 amyloid precursor protein binding to copper. FEBS Letters, 1994, 349, 109-116.	1.3	230
498	Interaction between the zinc(II) and the heparin binding site of the Alzheimer's disease β A4 amyloid precursor protein (APP). FEBS Letters, 1994, 355, 151-154.	1.3	86
499	Transforming growth factor β 2 mediates increase of mature transmembrane amyloid precursor protein in microglial cells. FEBS Letters, 1994, 342, 267-272.	1.3	46
500	Alzheimer's disease: a clearer definition of the genetic components. Medical Journal of Australia, 1994, 160, 243-244.	0.8	6
501	Amyloidogenicity of rodent and human β A4 sequences. FEBS Letters, 1993, 324, 231-236.	1.3	148
502	The Role of Extracellular Matrix in the Processing of the Amyloid Protein Precursor of Alzheimer's Disease. Annals of the New York Academy of Sciences, 1993, 695, 169-174.	1.8	15
503	Expression of L-APP mRNA in Brain Cells. Annals of the New York Academy of Sciences, 1993, 695, 183-189.	1.8	17
504	Human Brain β A4 Amyloid Protein Precursor of Alzheimer's Disease: Purification and Partial Characterization. Journal of Neurochemistry, 1992, 59, 1490-1498.	2.1	49

#	ARTICLE	IF	CITATIONS
505	An abnormality of plasma amyloid protein precursor in Alzheimer's disease. <i>Annals of Neurology</i> , 1992, 32, 57-65.	2.8	56
506	Human and rodent sequence analogs of Alzheimer's amyloid betaA4 share similar properties and can be solubilized in buffers of pH 7.4. <i>FEBS Journal</i> , 1991, 201, 61-69.	0.2	72
507	In-vitro matured human macrophages express Alzheimer's β A4-amyloid precursor protein indicating synthesis in microglial cells. <i>FEBS Letters</i> , 1991, 282, 335-340.	1.3	54
508	Amyloid Precursor Protein (APP) and β A4 Amyloid in the Etiology of Alzheimer's Disease: Precursor-Product Relationships in the Derangement of Neuronal Function. <i>Brain Pathology</i> , 1991, 1, 241-251.	2.1	181
509	Synthesis and secretion of Alzheimer amyloid β A4 precursor protein by stimulated human peripheral blood leucocytes. <i>FEBS Letters</i> , 1990, 277, 261-266.	1.3	71
510	Retinoic acid induced differentiated neuroblastoma cells show increased expression of the β A4 amyloid gene of Alzheimer's disease and an altered splicing pattern. <i>FEBS Letters</i> , 1990, 269, 305-310.	1.3	101
511	The Pathology of the Amyloid A4 Precursor of Alzheimer's Disease. <i>Annals of Medicine</i> , 1989, 21, 89-90.	1.5	10
512	Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. <i>Cell</i> , 1989, 57, 115-126.	13.5	1,249
513	Rett syndrome: Abnormal membrane-bound lamellated inclusions in neurons and oligodendroglia. <i>American Journal of Medical Genetics Part A</i> , 1988, 29, 365-368.	2.4	24
514	Neuropathology of Unconventional Virus Infections: Molecular Pathology of Spongiform Change and Amyloid Plaque Deposition. <i>Novartis Foundation Symposium</i> , 1988, 135, 24-36.	1.2	6
515	The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. <i>Nature</i> , 1987, 325, 733-736.	13.7	4,546
516	Neuronal Origin of Cerebral Amyloidogenic Proteins: Their Role in Alzheimer's Disease and Unconventional Virus Diseases of the Nervous System. <i>Novartis Foundation Symposium</i> , 1987, 126, 49-64.	1.2	7
517	Increased Cerebral Glucose-6-Phosphate Dehydrogenase Activity in Alzheimer's Disease May Reflect Oxidative Stress. <i>Journal of Neurochemistry</i> , 1986, 46, 1042-1045.	2.1	224
518	Rapidly progressive dementia with ataxia. <i>Medical Journal of Australia</i> , 1986, 144, 24-28.	0.8	1
519	Syndromes of amyotrophic lateral sclerosis and dementia: Relation to transmissible Creutzfeldt-Jakob disease. <i>Annals of Neurology</i> , 1983, 14, 17-26.	2.8	147
520	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 0, , .	0.4	2
521	Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention Trials. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	3